Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 4/20 | 0.49 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | HRH2 | P25021 | 3/20 | 0.44 |
| ▸ | HRH1 | P35367 | 3/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.43 |
| ▸ | YAP1 | P46937 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2894161 | 1.00 | ITGB3 (0.49) | ITGB3ITGA2BMAPK1HRH2HRH1 | |
| SCHEMBL2894162 | 1.00 | ITGB3 (0.49) | ITGB3ITGA2BMAPK1HRH2HRH1 | |
| SCHEMBL2897693 | 0.93 | HRH2 (0.42) | ITGB3ITGA2BMAPK1HRH2HRH1 | |
| SCHEMBL2897695 | 0.93 | HRH2 (0.42) | ITGB3ITGA2BMAPK1HRH2HRH1 | |
| SCHEMBL2898097 | 0.93 | HRH2 (0.42) | ITGB3ITGA2BMAPK1HRH2HRH1 | |
| SCHEMBL2895126 | 0.90 | ITGB3 (0.52) | ITGB3ITGA2BMAPK1HRH2HRH1 | |
| SCHEMBL2891888 | 0.90 | ITGB3 (0.52) | ITGB3ITGA2BMAPK1HRH2HRH1 | |
| SCHEMBL2895540 | 0.89 | GPR119 (0.49) | ITGB3ITGA2BMAPK1HRH2HRH1 | |
| SCHEMBL2897187 | 0.89 | GPR119 (0.49) | ITGB3ITGA2BMAPK1HRH2HRH1 | |
| SCHEMBL2895536 | 0.89 | GPR119 (0.49) | ITGB3ITGA2BMAPK1HRH2HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286112-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2010-11-11 | — | — | US | disclosed |
| US-20100286112-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2010-11-11 | — | — | US | disclosed |
| US-20100286112-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286112-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | GPR119, DPP4, DPP9 | ITGB3 4005/4885ITGA2B 3156/4885MAPK1 3875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.